Kymera Therapeutics Inc
(NAS:KYMR)
$
50.05
-1.84 (-3.55%)
Market Cap: 3.24 Bil
Enterprise Value: 2.90 Bil
PE Ratio: 0
PB Ratio: 3.63
GF Score: 47/100 Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022 / 12:00PM GMT
Release Date Price:
$27.81
(+2.17%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Great. Good morning. Welcome, everyone. Let us go ahead and get started. My name is Vikram Purohit. I am one of the biotech analyst at the Morgan Stanley Research. This is the fireside chat with Kymera Therapeutics, and I am very happy to have with me on the stage, CEO, Nello Mainolfi. Nello, thanks for joining us.
Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thanks, Vikram. Great to be here.
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
And before we get started, let me read a brief disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. With that, let us get started. Nello, before we dive into the pipeline, maybe you could
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot